Analysis of HER2 expression changes from breast primary to brain metastases and the impact of HER2-low expression on overall survival.
Saved in:
| Title: | Analysis of HER2 expression changes from breast primary to brain metastases and the impact of HER2-low expression on overall survival. |
|---|---|
| Authors: | Pereslete AM; Herbert Wertheim College of Medicine, Florida International University, Miami, Florida, USA.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, Massachusetts, USA.; Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Hughes ME; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, Massachusetts, USA.; Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Martin AR; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, Massachusetts, USA.; Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Files J; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, Massachusetts, USA.; Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Nguyen K; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, Massachusetts, USA.; Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Buckley L; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, Massachusetts, USA.; Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Patel A; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, Massachusetts, USA.; Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Moore A; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, Massachusetts, USA.; Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Winer EP; Yale Cancer Center, New Haven, Connecticut, USA.; Harvard Medical School, Boston, Massachusetts, USA.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, Massachusetts, USA.; Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Dillon D; Harvard Medical School, Boston, Massachusetts, USA.; Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts, USA., Li T; Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Tolaney SM; Harvard Medical School, Boston, Massachusetts, USA.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, Massachusetts, USA.; Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Lin NU; Harvard Medical School, Boston, Massachusetts, USA.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, Massachusetts, USA.; Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Sammons SL; Harvard Medical School, Boston, Massachusetts, USA.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, Massachusetts, USA.; Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA. |
| Source: | Neuro-oncology [Neuro Oncol] 2025 Jan 12; Vol. 27 (1), pp. 184-194. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Oxford University Press Country of Publication: England NLM ID: 100887420 Publication Model: Print Cited Medium: Internet ISSN: 1523-5866 (Electronic) Linking ISSN: 15228517 NLM ISO Abbreviation: Neuro Oncol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1523-5866 |
|---|---|
| DOI: | 10.1093/neuonc/noae163 |
